Shots: Osivax & GC Biopharma have entered a long-term collaboration to develop & commercialize a next-generation seasonal influenza vaccine combining OVX836, Osivax’s T-cell vaccine, with GC FLU, GC Biopharma’s WHO-prequalified seasonal flu vaccine The single-injection combination is designed to generate complementary immune responses, with T cells targeting the conserved NP antigen alongside antibodies against the…